Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Healius Limited ( (AU:HLS) ).
Healius Limited’s 2025 Annual General Meeting highlighted the company’s ongoing commitment to the Australian pathology sector, emphasizing its role in modern medicine through diagnostic services. The Chair’s address acknowledged challenges such as the disparity between Medicare rebates and rising costs, indicating a need for sustainable service provision strategies. The meeting underscored Healius’s position as a key player in the industry, particularly in underserved areas, and its efforts to adapt to industry disruptions.
The most recent analyst rating on (AU:HLS) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is a leading healthcare company in Australia, providing specialty pathology services nationwide. With over 8,000 employees and a significant footprint of centers, Healius is committed to offering quality, affordable, and accessible healthcare. It is the second-largest provider of pathology services in Australia and the largest in regional, remote, and indigenous communities.
Average Trading Volume: 4,834,879
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$580.9M
Learn more about HLS stock on TipRanks’ Stock Analysis page.